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recommend Neuroimmunomodulation to anyone interested in gaining an introduction
to an exciting field with a long future.
STEPHEN B. BHARUCHA
MedicalStudent
Yale University School ofMedicine
ACUTE CORONARY INTERVENTION. Edited by Eric J. Topol. New York, Alan R. Liss,
Inc., 1987. 302 pp. $49.50.
Treatment for the patient with an acute myocardial infarction (AMI) has changed
considerably in the past 50 years. Initially, the treatment simplyconsisted ofrest. With
the introduction of antiarrhythmics and coronary care units, mortality from AMI
decreased substantially. Over the past several years, the treatment ofAMI has evolved
further with the useofthrombolytic agents and emergency percutaneous transluminal
angioplasty (PTCA).
Acute Coronary Intervention deals with this rapidly advancing and exciting area.
Edited by Eric J. Topol, this book provides a thorough discussion of both the basic
science research and the clinical trials in the field.
The first section of this volume concerns the thrombolytic agents. The biochemical
aspects and pathophysiology of streptokinase (SK), urokinase (UK), and tissue-type
plasminogen activator (tPA) are presented in depth. This section is very helpful
because it clears up any confusion the reader may have had about the differences
between these drugs. SK, by forming a plasminogen-streptokinase complex, which
then activates plasminogen to form plasmin, causes a "systemic lytic state." Unlike
SK, tPA is derived from human tissue and normally has a low affinity for circulating
plasminogen. When bound to fibrin, however, tPA binds plasminogen tightly and
causes a fibrin-specific thrombolysis and, in theory, avoids a systemic lytic state.
With this background, Topol includes a section entitled "Lessons From Major
Clinical Trials," which examines the following trials: the Western Washington, the
GISSI (Italian Group for the Study of Streptokinase in Myocardial Infarction), the
TIMI (Thrombolysis in Myocardial Infarction), the TAMI (Thrombolysis in Acute
Myocardial Infarction), and the European Cooperative. For each trial, the author
outlines the purpose ofthe study and provides a flow chart ofthe protocol. In general,
this section is excellent. In the chapter discussing the GISSI trial, however, the author
showed that short-term intravenous SK was effective in reducing mortality in AMI at
one year. From this finding he goes on to add, however, "Thrombolysis with high dose
intravenous SK can definitely be seen as a recommended treatment for the majority of
patients admitted to CCUs within at least 6 hours of the onset of diagnostic pain; its
beneficial effects on mortality are beyond question, and its overall risk profile is
clinicallyacceptable." Comments such as this, which advocate anextremelyaggressive
approach to the treatment of AMI, are common throughout the book. While these
comments may be supported by clinical studies, it would have been interesting to have
included a chapter on the economic implications ofthese results.
In the past few years, major advances have been made in the management ofAMI.
Thrombolytic therapy and angioplasty have an important role incardiology, a role that
is being constantly refined. Acute Coronary Intervention has assembled many timelyBOOK REVIEWS 557
and comprehensive papers in a well-organized and easily readable format, an excellent
resource for all cardiologists and emergency medicine physicians.
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KAWASAKI DISEASE. Edited by Stanford T. Shulman. New York, Alan R. Liss, Inc.,
1987. 591 pp. $98.00.
This 591-page volume has a publication date of 1987 and is made up of 58
manuscripts/chapters and 28 poster abstracts from papers delivered at The Second
International Kawasaki Disease Symposium, held in Kauai, Hawaii, November 30 to
December 3, 1986. There is a 10'/2 page index.
Kawasaki disease (KD) is an apparently infectious disease first recognized in Japan
by Tomisaku Kawasaki in 1967. Initially it was called the acute febrile mucocutaneous
lymph node syndrome (MCLNS or MCLS). This is a vasculitis-type disease with a
conspicuous rash that lasts many weeks. The major and most serious complication is
the development ofcoronary artery aneurysms that may rupture or lead to myocardial
infarction, although most frequently the aneurysms regress, and the patient returns to
full health. Despite considerable research and many interesting leads, the etiology and
pathogenetic mechanisms remain obscure.
With so many papers, this volume covers all ofthe major research and clinical areas
that have been investigated. The papers are grouped in sections on epidemiology,
etiology, pathogenesis and mechanisms, cardiology, therapy, and future directions.
Each of these topics is covered in reasonable depth, although the chapters vary in
length (2 to 15 single-column pages), detail, and, inevitably, quality. The opening
chapter on thediscovery ofthediseaseand thespreadofinformation and interest about
it to the U.S. is written, appropriately, by T. Kawasaki himself. Then there are seven
papers from all over the world on the epidemiology of KD, with the most extensive
presentations from Japan and the U.S. These chapters are among the most complete
and useful in the entire book and can stand alone without any need to consult
references. Following this group ofpapers are eight on etiologic agents. None of these
papers is definitive, but they certainly cover the major suspected agents and the stateof
the art in the search for a cause. These papers include three on the possibility of a
retroviral etiology, an area that has received considerable attention. Following them is
a short discussion ofetiology by Yale's own Alfred S. Evans, in which he points out the
need to adhere to the standard of the Henle-Koch postulates, how they might be
applied in contemporary research, and how etiologic agents were discovered in
analogous diseases.
The remaining sections of the book are more clinical and deal with data assembled
on the cardiac complications, their management, and attempts at therapy for short-
ening the course of the disease and preventing complications. In fact, this aspect is
where the greatest advances have come, with demonstration of efficacy of salicylates
and intravenous gamma globulins for symptomatic treatment and prevention of
coronary artery aneurysms. Many of these papers are not as informative, clear, and